Brücher B L, Roder J D, Fink U, Stein H J, Busch R, Siewert J R
Chirurgische Klinik and Poliklinik, Klinikum rechts der Isar der Technischen Universität München, Deutschland.
Dig Surg. 1998;15(1):42-51. doi: 10.1159/000018585.
We report a retrospective analysis of 71 patients, operated for primary small bowel tumors (SBT): 47 malignant (66.2%) and 24 benign (33.8%) tumors. Of the malignant tumors, adenocarcinomas predominated (38.3%), followed by neuroendocrine tumors (31.9%), Non-Hodgkin lymphomas (NHL) (12.8%), leiomyosarcomas (10.6%) and other rare entities (6.4%). Morbidity of surgical treatment was 16. 9%, 30-day mortality 7%. The estimated 5-year survival rate in malignant lesions was 31.8%. Univariate analysis identified the presence of distant metastasis and the resection status (R status) as prognostic factors (p = 0.034 and p = 0.001). There was no influence of T, N status or grading on survival. A complete macroscopic and microscopic tumor resection has to be the aim of any curative surgical approach in patients with SBT.
我们报告了一项对71例因原发性小肠肿瘤（SBT）接受手术治疗患者的回顾性分析：47例为恶性肿瘤（66.2%），24例为良性肿瘤（33.8%）。在恶性肿瘤中，腺癌占主导（38.3%），其次是神经内分泌肿瘤（31.9%）、非霍奇金淋巴瘤（NHL）（12.8%）、平滑肌肉瘤（10.6%）和其他罕见类型（6.4%）。手术治疗的发病率为16.9%，30天死亡率为7%。恶性病变的估计5年生存率为31.8%。单因素分析确定远处转移的存在和切除状态（R状态）为预后因素（p = 0.034和p = 0.001）。T、N状态或分级对生存率无影响。对于SBT患者，任何根治性手术方法的目标都必须是实现肿瘤的完整宏观和微观切除。
